{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:53:12Z","timestamp":1794243192830,"version":"4.9.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"crossref","award":["DMR-106-160; DMR-107-012"],"award-info":[{"award-number":["DMR-106-160; DMR-107-012"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-019-1534-4","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T10:04:13Z","timestamp":1567764253000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Spironolactone ameliorates endothelial dysfunction through inhibition of the AGE\/RAGE axis in a chronic renal failure rat model"],"prefix":"10.1186","volume":"20","author":[{"given":"Chun-Cheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Sheng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiz-Tzung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"key":"1534_CR1","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1681\/ASN.V1071606","volume":"10","author":"PS Parfrey","year":"1999","unstructured":"Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol. 1999;10:1606\u201315.","journal-title":"J Am Soc Nephrol"},{"key":"1534_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1681\/ASN.2004030203","volume":"16","author":"RN Foley","year":"2005","unstructured":"Foley RN, Murray AM, Li S, Herzog CA, Marshall McBean A, et al. Chronic kidney disease and the risk of cardiovascular disease, renal replacement, and death in the United States medicare population, 1998-1999. J Am Soc Nephrol. 2005;16:489\u201395.","journal-title":"J Am Soc Nephrol"},{"key":"1534_CR3","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1046\/j.1523-1755.2002.00600.x","volume":"62","author":"J Himmelfarb","year":"2002","unstructured":"Himmelfarb J, Stenvinkel P, Alp Ikizler T, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524\u201338.","journal-title":"Kidney Int"},{"key":"1534_CR4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/sj.ki.5000330","volume":"70","author":"K Taki","year":"2006","unstructured":"Taki K, Takayama F, Tsuruta Y, Niwa T. Oxidative stress, advanced glycation end products, and coronary artery calcification in hemodialysis patients. Kidney Int. 2006;70:218\u201324.","journal-title":"Kidney Int"},{"key":"1534_CR5","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.ejheart.2007.09.009","volume":"9","author":"JWL Hartog","year":"2007","unstructured":"Hartog JWL, Voors AA, Bakker SJL, Smit AJ, van Veldhuisen DJ. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail. 2007;9:1146\u201355.","journal-title":"Eur J Heart Fail"},{"key":"1534_CR6","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/ki.1997.160","volume":"51","author":"T Miyata","year":"1997","unstructured":"Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, et al. Implication of am increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int. 1997;51:1170\u201381.","journal-title":"Kidney Int"},{"issue":"6","key":"1534_CR7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/ajh\/hpt014","volume":"26","author":"QF Huang","year":"2013","unstructured":"Huang QF, Sheng CS, Liu M, Li FH, Li Y, Wang JG. Arterial stiffness and wave reflections in relation to plasma advanced glycation end products in a Chinese population. Am J Hypertens. 2013;26(6):754\u201361.","journal-title":"Am J Hypertens"},{"key":"1534_CR8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/01.HYP.0000164574.60279.ba","volume":"46","author":"MT Schram","year":"2005","unstructured":"Schram MT, Schalkwijk CG, Bootsma AH, Fuller JH, Chaturvedi N, Stehouwer CDA, et al. Advanced glycation end products are associated with pulse pressure in type 1 diabetes. The EURODIAB prospective complications study. Hypertension. 2005;46:232\u20137.","journal-title":"Hypertension."},{"key":"1534_CR9","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.2337\/diabetes.53.7.1813","volume":"53","author":"JM Forbes","year":"2004","unstructured":"Forbes JM, Yee TL, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes. 2004;53:1813\u201323.","journal-title":"Diabetes."},{"issue":"1","key":"1534_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147771","volume":"11","author":"CC Wang","year":"2016","unstructured":"Wang CC, Wang YC, Wang GJ, Shen MY, Chang YL, Liou SY, et al. Skin autofluorescence is associated with endothelial dysfunction in uremic subjects on hemodialysis. PLoS One. 2016;11(1):e0147771.","journal-title":"PLoS One"},{"issue":"3","key":"1534_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.cardfail.2006.01.002","volume":"12","author":"HM Thai","year":"2006","unstructured":"Thai HM, Do BQ, Tran TD, Gaballa MA, Goldman S. Aldosterone antagonism impoves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production. J Card Fail. 2006;12(3):240\u20135.","journal-title":"J Card Fail"},{"key":"1534_CR12","doi-asserted-by":"crossref","unstructured":"Quach K, Lvtvyn L, Baigent C, Bueti J, Garg AX, Hawley C, et al. The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: a systemic review and meta-analysis. Am J Kidney Dis. 2016.","DOI":"10.1053\/j.ajkd.2016.04.011"},{"issue":"2","key":"1534_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/jch.12628","volume":"18","author":"C Lin","year":"2016","unstructured":"Lin C, Zhang Q, Zhang H, Lin A. Long-term effects of low-dose spironolactone on chronic dialysis patients: a randomized placebo-controlled study. J Clin Hypertens. 2016;18(2):121\u20138.","journal-title":"J Clin Hypertens"},{"key":"1534_CR14","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/j.1440-1681.2010.05445.x","volume":"37","author":"H Toba","year":"2010","unstructured":"Toba H, Nakashima K, Oshima Y, Kojima Y, Tojo C, Nakano A, Wang J, Kobara M, Nakata T. Erytheropoietin prevents vascular inflammation and oxidative stress in subtotal nephrectomized rat aorta beyond harmatopoiesis. Clin Exp Pharmacol Physiol. 2010;37:1139\u201346.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1534_CR15","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1097\/01.hjh.0000249699.04113.36","volume":"24","author":"S Vettoretti","year":"2006","unstructured":"Vettoretti S, Ochodnicky P, Buikema H, Henning RH, Alex Kluppel C, de Zeeuw D, van Dokkum RPE. Altered myogenic constriction and endothelium-derived hyperpolarizing factor-mediated relaxation in small mesenteric arteries of hypertensive subtotally nephrectomized rats. J Hypertens. 2006;24:2215\u201323.","journal-title":"J Hypertens"},{"key":"1534_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/403460","volume":"2013","author":"YK Chuah","year":"2013","unstructured":"Chuah YK, Basir R, Talib H, Tie TH, Nordin N. Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflam. 2013;2013:403460.","journal-title":"Int J Inflam"},{"key":"1534_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.redox.2013.12.016","volume":"2","author":"C Ott","year":"2014","unstructured":"Ott C, Jacobs K, Haucke E, Santos AN, Grune T, Simm A. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014;2:411\u201329.","journal-title":"Redox Biol"},{"key":"1534_CR18","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1093\/eurheartj\/eht095","volume":"34","author":"N Sch\u00e4fer","year":"2013","unstructured":"Sch\u00e4fer N, Lohmann C, Winnik S, van Tits LJ, Miranda MX, Vergopoulos A, Ruschitzka F, Nussberger J, Berger S, L\u00fcscher TF, Verrey F, Matter CM. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. Eur Heart J. 2013;34:3515\u201324.","journal-title":"Eur Heart J"},{"key":"1534_CR19","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00210-014-1048-3","volume":"387","author":"H Adel","year":"2014","unstructured":"Adel H, Taye A, Khalifa M. Spironolactone improves endothelial dysfunction in Streptozocin-induced diabetic rats. Naunyn Schmiedeberg's Arch Pharmacol. 2014;387:1187\u201397.","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"1534_CR20","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/ki.2012.184","volume":"82","author":"LL Zhou","year":"2012","unstructured":"Zhou LL, Cao W, Xie C, Tian J, Zhou Z, Zhou Q, Zhu P, Li A, Liu Y, Miyata T, Hou FF, Nie J. The receptor of adcnaced glycation end products play a central role in advanced oxidation products-induced podocyte apoptosis. Kidney Int. 2012;82:759\u201370.","journal-title":"Kidney Int"},{"issue":"12","key":"1534_CR21","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1096\/fj.02-1102fje","volume":"17","author":"JM Forbes","year":"2003","unstructured":"Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, Cooper ME. The breakdown of pre-existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. 2003;17(12):1762\u20134.","journal-title":"FASEB J"},{"issue":"7255","key":"1534_CR22","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nature08197","volume":"460","author":"T Finkel","year":"2009","unstructured":"Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature. 2009;460(7255):587\u201391.","journal-title":"Nature."},{"key":"1534_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.toxlet.2018.10.025","volume":"301","author":"M Rezaei","year":"2019","unstructured":"Rezaei M, Keshtzar E, Khodayer MJ, Javadipour M. SirT3 regulates diabetogenic effects caused by arsenic: an implication for mitochondrial complex II modification. Toxicol Lett. 2019;301:24\u201333.","journal-title":"Toxicol Lett"},{"issue":"24","key":"1534_CR24","doi-asserted-by":"publisher","first-page":"8807","DOI":"10.1128\/MCB.01636-07","volume":"27","author":"DB Lombard","year":"2007","unstructured":"Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS, Mostoslavsky R, et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol. 2007;27(24):8807\u201314.","journal-title":"Mol Cell Biol"},{"key":"1534_CR25","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/embor.2011.65","volume":"12","author":"Y Chen","year":"2011","unstructured":"Chen Y, Zhang J, Lin Y, Lei Q, Guan KL, Zhao S, Xiong Y. Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Rep. 2011;12:534\u201341.","journal-title":"EMBO Rep"},{"key":"1534_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.freeradbiomed.2013.05.002","volume":"63","author":"AH Tseng","year":"2013","unstructured":"Tseng AH, Shieh SS, Wang DL. SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage. Free Radic Biol Med. 2013;63:222\u201334.","journal-title":"Free Radic Biol Med"},{"key":"1534_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12933-017-0531-9","volume":"16","author":"X Ren","year":"2017","unstructured":"Ren X, Ren L, Wei Q, Shao H, Chen L, Liu N. Advanced glycation end-peoducts decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Cardiovasc Diabetol. 2017;16:52.","journal-title":"Cardiovasc Diabetol"},{"key":"1534_CR28","doi-asserted-by":"publisher","first-page":"H647","DOI":"10.1152\/ajpheart.01271.2010","volume":"301","author":"NS Zinkevich","year":"2011","unstructured":"Zinkevich NS, Gutterman DD. ROS induced ROS release in vascular biology: redox-redox signaling. Am J Physiol Heart Circ Physiol. 2011;301:H647\u201353.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"1534_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1742-7843.2011.00785.x","volume":"110","author":"AC Montezano","year":"2012","unstructured":"Montezano AC, Touyz RM. Reactive oxygen species ans endothelial function - role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases. Basic Clin Pharmacol Toxicol. 2012;110(1):87\u201394.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1534_CR30","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1161\/CIRCULATIONAHA.109.877191","volume":"120","author":"F Violi","year":"2009","unstructured":"Violi F, Sanguigni V, Carnevale R, Plebani A, Rossi P, Finocchi A, et al. Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. Circulation. 2009;120:1616\u201322.","journal-title":"Circulation."},{"issue":"2","key":"1534_CR31","first-page":"329","volume":"10","author":"A Taye","year":"2011","unstructured":"Taye A, Morawietz H. Spironolactone inhibits NADPH oxidase-induced oxidative stress and enhances eNOS in human endothelial cells. Iran J Pharm Res. 2011;10(2):329\u201337.","journal-title":"Iran J Pharm Res"},{"key":"1534_CR32","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1093\/ndt\/gfs014","volume":"27","author":"K S\u00e1nchez-Pozos","year":"2012","unstructured":"S\u00e1nchez-Pozos K, Barrera-Chimal J, Garz\u00f3n-Muvdi J, P\u00e9rez-Villalva R, Rodr\u00edguez-Romo R, Cruz C, et al. Recovery from ischemic acute kidney injury by spironolactone administration. Nephrol Dial Transplant. 2012;27:3160\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1534_CR33","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1681\/ASN.2005111196","volume":"17","author":"SY Han","year":"2006","unstructured":"Han SY, Kim CH, Kim HS, Jee YH, Song HK, Lee MH, et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Sec Nephrol. 2006;17:1362\u201372.","journal-title":"J Am Sec Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1534-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1534-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1534-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T18:43:25Z","timestamp":1664304205000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1534-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1534"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1534-4","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,6]]},"assertion":[{"value":"10 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal study protocols were approved by the Institutional Animal Use and Care Committee of China Medical University (protocol number: 104\u2013272).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"351"}}